Perclose Proglide
Payments companies reported to CMS as associated with Perclose Proglide. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Perclose Proglide, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Perclose Proglide
These are the largest totals companies reported as associated with Perclose Proglide. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Brian Derubertis | New York, NY | Vascular Surgery | $21,445.72 |
| Mehran Massumi | Houston, TX | Interventional Cardiology | $19,658.57 |
| Arthur Lee | Gainesville, FL | Interventional Cardiology | $19,310.14 |
| Peter Faries | New York, NY | Vascular Surgery | $18,900.00 |
| Matthew Bunte | Kansas City, MO | Interventional Cardiology | $17,893.64 |
| Srinivas Tummala | Pembroke Pines, FL | Vascular & Interventional Radiology | $16,849.19 |
| Sahil Parikh | New York, NY | Interventional Cardiology | $16,451.55 |
| Prakash Krishnan | New York, NY | Interventional Cardiology | $16,343.23 |
| Christian Bianchi | Loma Linda, CA | Surgery | $13,543.87 |
| Daniella Kadian Dodov | New York, NY | Internal Medicine | $12,230.85 |
Prescribed Perclose Proglide?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.